Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 2 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
1(100.0%)
1Total
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (2)

Showing 2 of 2 trials
NCT05083780Phase 1Active Not Recruiting

Hydroxychloroquine and Chlorphenesin Carbamate in Combination With mFOLFIRINOX in Pancreatic Cancer

Role: collaborator

NCT04932343Unknown

Comparison of Genomic and Transcriptomic Patterns Between CTC and Metastatic Tumormetastatic Tumor

Role: collaborator

All 2 trials loaded